ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

AmerisourceBergen & Biopharmaceutical Companies Discuss Strategies to Advance Pharmaceutical Innovation and Access at ThinkLive Commercialization Conference

Global healthcare company AmerisourceBergen (AB) convened leaders and innovators across the biopharmaceutical industry on Monday for its ThinkLive Commercialization summit, an annual event centered on strategies and solutions that help companies maximize success at every stage of the product lifecycle. During the summit in Las Vegas, leaders discussed the challenges and considerations companies face when bringing a product to market, and how AB is strengthening its portfolio of global clinical and commercialization services to help partners launch products, drive success and enhance patient outcomes.

“As the pace of transformation in healthcare continues to accelerate, biopharmaceutical companies need to be flanked by a partner that can help them navigate the challenges of a dynamic and ever-changing market. We continue to make strategic investments and deploy new solutions to ensure we’re best positioned to support our partners’ evolving needs—whether it’s cryogenic storage to support cell and gene therapies or innovative services to increase speed-to-therapy,” said Bob Mauch, EVP & Group President at AmerisourceBergen. ThinkLive Commercialization serves as a critical opportunity for us to connect with our partners and discuss emerging challenges and opportunities as we work together to advance pharmaceutical innovation and access.”

This year’s conference programming included remarks from Mauch and AmerisourceBergen Chairman, President & CEO Steve Collis, as well as dynamic panel discussions and presentations on new solutions. The panel discussions covered a variety of topics, including policy and the impact to biopharmaceutical companies and the role of data and technology in increasing speed-to-therapy and optimizing product success. During a leadership panel, AB executives discussed key priorities, strategic investments and partnerships the company is exploring to improve access to advanced therapies globally and enhance the support it provides biopharmaceutical companies.

Attendees also heard directly from AB leaders on the company’s expanding portfolio of solutions and services, which include FormularyDecisions, a secure platform that facilitates the exchange of information between biopharmaceutical companies and healthcare decision makers, and FirstView Financial, a fintech provider that delivers innovative digital payment processing services to support patient affordability and access programs. Following the new solutions session, attendees joined breakout sessions focused on solutions that AB is developing or expanding.

“Our biopharmaceutical partners are at the forefront of medical innovation—working daily to develop novel products to address unmet medical needs. As their partner, we are focused on delivering best-in-class support across the product lifecycle to simplify the path to commercialization, unlock product potential and accelerate patient access to innovative therapies,” said Willis Chandler, President of Manufacturer Services, Global Sourcing and Commercial Solutions at AmerisourceBergen. “Through these sessions at ThinkLive, we had the unique opportunity to present the solutions we are developing or exploring to a room full of our partners. Their feedback will help inform the next stages of development and ultimately enable us to strengthen the value we offer across the commercialization journey.”

AmerisourceBergen will host its first combined ThinkLive event in October, which will offer customized content for all attendees. For more in-depth perspectives from ThinkLive Commercialization and AmerisourceBergen on commercialization strategies, innovative therapies and more, please visit: https://amerisourcebergen.com/manufacturer-solutions/how-to-maximize-your-drug-commercialization-investments.

About AmerisourceBergen

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies, and providers, we create unparalleled access, efficiency, and reliability for human and animal health. Our 42,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at https://amerisourcebergen.com/.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.02
-4.28 (-1.86%)
AAPL  271.38
+1.68 (0.62%)
AMD  261.73
-2.60 (-0.99%)
BAC  53.22
+0.64 (1.21%)
GOOG  286.28
+11.11 (4.04%)
META  678.39
-73.28 (-9.75%)
MSFT  525.55
-16.00 (-2.95%)
NVDA  202.96
-4.08 (-1.97%)
ORCL  261.29
-14.01 (-5.09%)
TSLA  445.99
-15.52 (-3.36%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.